Gadolinium-associated nephrogenic systemic fibrosis

American Family Physician

Volumn 80, Issue 7, 2009, Pages 711-714

  Schlaudecker, Jeffrey D ^a,b   Bernheisel, Christopher R ^a,b  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b CHRIST HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; CORTICOSTEROID; GADODIAMIDE; GADOLINIUM; GADOLINIUM PENTETATE; GADOVERSETAMIDE; METHOTREXATE; THALIDOMIDE; THIOSULFATE;

ACUTE KIDNEY FAILURE; BLOOD VESSEL INJURY; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; DISEASE ASSOCIATION; FOOD AND DRUG ADMINISTRATION; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HEPATORENAL SYNDROME; HUMAN; ISCHEMIA; JOINT CONTRACTURE; KIDNEY FAILURE; LIMB INJURY; LIVER TRANSPLANTATION; MORTALITY; NEPHROGENIC SYSTEMIC FIBROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOMYELITIS; PATHOPHYSIOLOGY; PATIENT ASSESSMENT; PERITONEAL DIALYSIS; PLASMAPHERESIS; PNEUMONIA; PUVA; RESPIRATORY FAILURE; REVIEW; RISK ASSESSMENT; SEPSIS; SKIN BIOPSY; SKIN EDEMA; SKIN INDURATION; THROMBOSIS; TISSUE INJURY;

EID: 70349651385     PISSN: 0002838X     EISSN: 0002838X     Source Type: Journal    
DOI: None     Document Type: Review

References (21)

1. Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit PE. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet. 2000;356(9234):1000-1001.
2. Ting WW, Stone MS, Madison KC, Kurtz K. Nephrogenic fibrosing dermopathy with systemic involvement. Arch Dermatol. 2003;139(7):903-906. (Pubitemid 36898926)
3. Cowper SE. Nephrogenic fibrosing dermopathy: the first 6 years. Curr Opin Rheumatol. 2003;15(6):785-790. (Pubitemid 38156308)
4. Grobner T. Gadolinium - a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? [published correction appears in Nephrol Dial Transplant. 2006;21(6):1745]. Nephrol Dial Transplant. 2006;21(4):1104-1108. (Pubitemid 44063150)
5. High WA, Ayers RA, Chandler J, Zito G, Cowper SE. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol. 2007;56(1):21-26. (Pubitemid 46017000)
6. Boyd AS, Zic JA, Abraham JL. Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol. 2007;56(1):27-30. (Pubitemid 44969309)
7. Important drug warning for gadolinium-based contrast agents. U.S. Food and Drug Administration. September 2007. http://www.fda.gov/downloads /Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ UCM154532.pdf. Accessed March 11, 2009.
8. Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol. 2006;17(9):2359-2362. (Pubitemid 44300951)
9. Swaminathan S, Ahmed I, McCarthy JT, et al. Nephrogenic fibrosing dermopathy and high-dose erythropoietin therapy. Ann Intern Med. 2006;145(3):234-235. (Pubitemid 46780577)
10. Wahba IM, Simpson EL, White K. Gadolinium is not the only trigger for nephrogenic systemic fibrosis: insights from two cases and review of the recent literature. Am J Transplant. 2007;7(10):2425-2432. (Pubitemid 47347864)
11. Sadowski EA, Bennett LK, Chan MR, et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology. 2007;243(1):148-157. (Pubitemid 46579705)
12. Cowper SE. Nephrogenic fibrosing dermopathy [NFD/NSF Web site]. 2001-2008. http://www.icnfdr.org. Accessed March 11, 2009.
13. Centers for Disease Control and Prevention (CDC). Nephrogenic fibrosing dermopathy associated with exposure to gadolinium-containing contrast agents - St. Louis, Missouri, 2002-2006. MMWR Morb Mortal Wkly Rep. 2007;56(7):137-141.
14. Saab G, Cheng S. Nephrogenic systemic fibrosis: a nephrologist's perspective. Hemodial Int. 2007;11(suppl 3):S2-S6. (Pubitemid 47491284)
15. Thomsen HS, for the European Society of Urogenital Radiology (ESUR). ESUR guideline: gadolinium - based contrast media and nephrogenic systemic fibrosis. Eur Radiol. 2007;17(10):2692-2696.
16. Gilliet M, Cozzio A, Burg G, Nestle FO. Successful treatment of three cases of nephrogenic fibrosing dermopathy with extracorporeal photopheresis. Br J Dermatol. 2005;152(3):531-536. (Pubitemid 40547128)
17. Baron PW, Cantos K, Hillebrand DJ, et al. Nephrogenic fibrosing dermopathy after liver transplantation successfully treated with plasmaphereisis. Am J Dermatopathol. 2003;25(3):204-209. (Pubitemid 36706461)
18. Weiss AS, Lucia MS, Teitelbaum I. A case of nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis. Nat Clin Pract Nephrol. 2007;3(2):111-115. (Pubitemid 46161003)
19. DiCarlo JB, Gupta EA, Solomon AR. A pediatric case of nephrogenic fibrosing dermopathy: improvement after combination therapy. J Am Acad Dermatol. 2006;54(5):914-916.
20. Yerram P, Saab G, Karuparthi PR, Hayden MR, Khanna R. Nephrogenic systemic fibrosis: a mysterious disease in patients with renal failure - role of gadolinium-based contrast media in causation and the beneficial effect of intravenous sodium thiosulfate. Clin J Am Soc Nephrol. 2007;2(2):258-263.
21. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298(17):2038-2047. (Pubitemid 350074801)